GALECTIN 3 AND ALDOSTERONE IN PATIENTS WITH ATRIAL FIBRILLATION AND METABOLIC SYNDROME

Aim. To study the levels of galectin 3 and aldostrone in blood serum of metabolic syndrome (MS) patients and atrial fibrillation (AF) for their importance evaluation. Material and methods. Totally 100 patients with MS (IDF, 2005) studied, of those 50 with AF: 28 with paroxysmal and 22 with persistent types. Controls were 50 almost healthy persons without cardiovascular pathology and metabolic disorders. Levels of galectin 3 and aldosterone in serum were measured by ELISA. All participants also underwent anthropometry, lipid profile and fasting glycemia measurements, transthoracal echocardiography.
Results. Galectin 3 level in MS and AF patients' serum was higher than in MS without AF and than in healthy persons (0,72 [0,44;1,36], 0,44 [0,42;1,22] and 0,32[0,28;0,42]ng/ml, resp.; p<0,01). Level of aldosterone in serum of MSwith AF patients was also 2 times higher than in healthy persons (202,2±82,4 and 98,4±51,2 pg/ml, p<0,001) and higher than in MS without AF (202,2±82,4 and 148,3±73,3 pg/ml, p<0,001). In patients with persisting AF there was higher level of galectine 3 and aldosterone comparing to those with paroxysmal. We found positive correlation in aldosterone levels and galectin 3 in serum (r=0,521, p<0,001).
Conclusion. Markers of myocardial fibrosis galectin 3 and aldosterone in serum of atrial fibrillation patients with metabolic syndrome were higher than in metabolic syndrome without that type of arrhythmia and than in healthy persons. In persisting type of atrial fibrillation the level of galectin3 was higher than in paroxysmal type.

1. Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin. Cardiol. 2008; 31:55-62.

2. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 2010; 31: 2369-429.

3. Chamberlain AM, Agarwal SK, Ambrose M, et al. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart J. 2010; 159: 159-64.

4. Milliez P, Girerd X, Plouin PR et al. Evidence for an increased rate of cardiovascular e vents in patients with primary aldosteronism. J. Am. Coll. Cardiol. 2005; 45: 1243-8.

5. Pei DA, Li L, Xu ZY, et al. Study on expression of mineralocorticoid receptor in human atria during atrial fibrillation. Zhonghua Xin Xue Guan Bing Za Zhi. 2007; 35: 114-8.

6. Shroff SC, Ryu K, MartovitzNL, etal. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J. Cardiovasc. Electrophysiol. 2006; 17: 534-41.

7. Calvier L, Miana M, Reboul P, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler. Thromb. Vase. Biol. 2013; 33: 67-75.

8. Calvier L, Martinez-Martinez E, Miana M, et al. The Impact of Galectin-3 Inhibition on Aldosterone-induced Cardiac and Renal Injuries. JACC Heart Fail. 2014; 1779: 388-96.

9. De Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011; 43: 60-8.

10. Rudolf A, BoerRA, Yu L, et al. Galectin-3 in cardiac remodeling and heart failure. Curr. Heart Fail. Rep. 2010; 7: 1-8.

11. Jennifer EH, XiaoyanY, Daniel L, et al. Galectin 3 and incident atrial fibrillation in the community. Am. Heart J. 2014; 167: 729-34.

12. lonin VA, Listopad OV, Soboleva AV, et al. Galectin 3 in patients with metabolic syndrome and atrial fibrillation. Arterial Hypertension J. 2014; 5: 101-8. Russian (Ионин В.А., ЛистопадО.В., Соболева А.В. Галектин 3 у пациентов с метаболическим синдромом и фибрилляцией предсердий. Артериальная гипертензия. 2014; 5:101-8.

13. WeberKT, Gerling 1С, Kiani MR et al. Aldosteronism in heart failure: a proinflammatory/ fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr. Drug. Targets. 2003; 4: 505-16.

14. Yen-Hung Lin, Chia-Hung Chou, Xue-Ming Wu, et al. Aldosterone Induced Galectin-3 Secretion In Vitro and In Vivo: From Cells to Humans. PLoS One. 2014; 9(9):e95254.